01—Abstract
Summary
Summary of the 8-K filed November 24, 2025. Cited figures are marked; the original filing is the authoritative source.
Halozyme Therapeutics, Inc. disclosed under Item 5.02 that Nicole LaBrosse, Senior Vice President and Chief Financial Officer, will continue to serve as CFO until the earliest of the hiring of a new chief financial officer, March 30, 2026, or an earlier date set by the Company (the "Separation Date"), and will then depart to pursue a new professional opportunity.
The company had previously announced this transition plan. On November 18, 2025, the Company and Ms. LaBrosse entered into a Transition and Release Agreement. Subject to her compliance with its obligations and her execution of a release of claims, she will be eligible for a 2025 annual bonus at 120%a of target-level individual performance, a cash severance payment under the Company's Severance Policy for a not-for-cause termination equal to her annual base salary (plus a pro-rated 2026 target bonus if separation occurs in 2026), and enhanced equity and benefits treatment.
Specifically, awards that would have vested by February 28, 2026 vest on the Separation Date if separation occurs before that date, vested options get an extended exercise period, unvested options accelerate on a Change in Control within one year after separation, and COBRA coverage costs are covered for one year. The filing states that the full agreement will be filed as an exhibit to the Company's Form 10-K for the year ending December 31, 2025. For investors, the key items are the impending CFO departure, the defined separation timeframe, and the severance and equity terms that define the cost and retention implications of the transition.
02—Key points
Key Highlights
- Nicole LaBrosse, SVP and Chief Financial Officer, will remain CFO until the earliest of a new CFO being hired, March 30, 2026, or an earlier date set by the Company, then depart for a new professional opportunity.
- A Transition and Release Agreement was entered into on November 18, 2025, conditioned on her compliance and execution of a release of claims.
- Her 2025 annual bonus is eligible at 120% of target-level individual performance.
- Severance equals her annual base salary, plus a pro-rated 2026 target bonus if separation occurs during 2026, under the Company's Severance Policy for a not-for-cause termination.
- Awards that would have vested by February 28, 2026 vest on the Separation Date if separation occurs before that date.
- Vested options remain exercisable for the shorter of one year after separation or the remaining option term; unvested options vest on a Change in Control within one year after separation.
- Company will cover COBRA continuation coverage cost under its group healthcare plans for one year after separation, subject to timely election.
03—Questions
Frequently Asked Questions
Who is leaving Halozyme as CFO and when?
Nicole LaBrosse, Senior Vice President and Chief Financial Officer, will continue as CFO until the earliest of when a new CFO is hired, March 30, 2026, or an earlier date the Company determines, and will then depart to pursue a new professional opportunity.
What severance and bonus benefits will the departing CFO receive?
Subject to compliance and a release of claims, she will receive a 2025 annual bonus at 120% of target-level individual performance and a cash payment under the Company's Severance Policy equal to her annual base salary, plus a pro-rated 2026 target bonus if she separates during 2026.
How will her equity awards be treated?
Awards that would have vested by February 28, 2026 vest on the Separation Date if she separates before that date. Vested options may be exercised for the shorter of one year after separation or their remaining term. Unvested options vest upon a Change in Control occurring within one year after separation. Otherwise, treatment follows a termination other than for cause under the applicable stock plan and award agreements.
Where can investors find the full terms of the agreement?
The filing states that the Transition and Release Agreement will be filed as an exhibit to the Company's Annual Report on Form 10-K for the year ending December 31, 2025.
04—Continue